Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


StarCaps marketer regroups

This article was originally published in The Tan Sheet

Executive Summary

In addition to voluntarily recalling its StarCaps weight-loss supplement, Balanced Health Products ceased working with the ingredient supplier and contract manufacturer linked to a batch tainted with the prescription diuretic bumetanide, says the firm's attorney, Marc Ullman. The response reflects the firm's accountability, and answers accusations that the adulteration is an indication that the regulation of dietary supplement products is lax, Ullman maintains. Representatives of National Football League players suspended when they tested positive for bumetanide blamed the loose regulation of the supplement industry for adulteration and, in turn, their positive tests (1"The Tan Sheet" Dec. 1, 2008, In Brief). Bumetanide is banned by the NFL because it may mask steroid use. Ullman said, "If it reflects on the industry, it is that the company performed the tests and started the recall." The New York City-based firm plans to reformulate the product but has not set a timetable for a re-launch, he says

You may also be interested in...

Diuretic found in StarCaps

Balanced Health Products voluntarily recalls one lot of the weight-loss supplement, which contained the undeclared diuretic bumetanide, FDA says Nov. 24. Bumetanide can cause serious loss of fluids and electrolytes and elevated uric acid concentrations. The New York City-based firm's president, Nikki Haskell, suspended shipment of StarCaps after National Football League players alleged the product was tainted after they were suspended for testing positive for bumetanide, which may mask steroid use (1"The Tan Sheet" Nov. 3, 2008, In Brief)

More Top-Level Pharma Changes In India, Cipla Gets CSO

Top-level personnel movement continues at pharma firms in India, with Cipla now appointing an ex-Amneal executive as its Chief Scientific Officer, while Abbott has effected a rejig at the helm.

India Acts To Limit Supply Disruption From Coronavirus

Indian pharmaceutical companies will soon be asked to seek a no objection certificate for the export of 12 APIs and their formulations, as the country deals with Chinese raw material supply disruptions on the back of the coronavirus crisis. However, the move is not expected to impact the export quantum for now.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts